Silence Therapeutics plc(SLN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Silence Therapeutics plc (SLN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SLN at 13.1/100 on a 32-signal composite quality model, placing it at rank #2,877 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Silence Therapeutics plc reports net income of $-12.3M, free cash flow of $1.5M. SLN trades on the Nasdaq exchange and files with the SEC under CIK 1479615. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silence Therapeutics plc directly from SEC EDGAR.

AI Quality Score

13.1/100

AI Rank

#2,877

Revenue

$0.00

Net Income

$-12.3M

Free Cash Flow

$1.5M

SLN key financials by period

Silence Therapeutics plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$559.0K$-88.6M—
FY 202410-K$43.3M$-45.3M-146.4%
FY 202310-K$31.6M$-54.2M—
FY 202210-K$21.7M$-50.3M—
FY 202020-F$5.3M——
SEC EDGAR: CIK 1479615 →
SLN

Silence Therapeutics plc

SLN
NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

13.1/100

Rank #2,877 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$0

Net Income

Q2 2026
EDGAR

$-12.27M

EPS (Diluted)

Q2 2026
EDGAR

$-0.09

Free Cash Flow

Q2 2026
EDGAR

$1.52M

Top Institutional Holders

as of Q2 2026
$246.13M total
Siren, L.L.C.
$36.36M+13.7%
TCG Crossover Management, LLC
$33.31M0.0%
Redmile Group, LLC
$23.77M0.0%
Nantahala Capital Management, LLC
$14.79M-37.3%
CITADEL ADVISORS LLC
$14.60MNew
Nextech Invest, Ltd.
$10.46M0.0%
MILLENNIUM MANAGEMENT LLC
$9.98M-15.4%
TFG Asset Management GP Ltd
$8.39M+21.3%
Soleus Capital Management, L.P.
$6.92MNew
BALYASNY ASSET MANAGEMENT L.P.
$6.71MNew

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…